Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA: 600420)
China
· Delayed Price · Currency is CNY 10.44
-0.35 (-3.24%)
Sep 6, 2024, 3:00 PM CST
Shanghai Shyndec Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 1,234 | 691.88 | 627.79 | 568.28 | 648.79 | 656.37 | Upgrade
|
| Depreciation & Amortization | 809.61 | 812.92 | 842.49 | 820.27 | 726.41 | 722.4 | Upgrade
|
| Other Amortization | 10.06 | 12.33 | 6.06 | 10.48 | 10.28 | 8.46 | Upgrade
|
| Loss (Gain) From Sale of Assets | 32.95 | 31.85 | 1.1 | -0.2 | -23.92 | 14.08 | Upgrade
|
| Asset Writedown & Restructuring Costs | 25.01 | 13.13 | 3.43 | 135.66 | 47.53 | 0.48 | Upgrade
|
| Loss (Gain) From Sale of Investments | -52.3 | -27.45 | -2.34 | 24.04 | 21.81 | 42.81 | Upgrade
|
| Provision & Write-off of Bad Debts | -36.1 | -18.05 | -17.59 | 24.87 | 26.24 | 6.76 | Upgrade
|
| Other Operating Activities | 183.45 | 399.15 | 393.7 | 405.67 | 405 | 490.92 | Upgrade
|
| Change in Accounts Receivable | 717.33 | 485.43 | 463.12 | -921.35 | -993.23 | -376.87 | Upgrade
|
| Change in Inventory | 49.51 | 163.27 | 625.24 | 195.31 | -966.64 | -30.75 | Upgrade
|
| Change in Accounts Payable | -390.77 | -832.62 | -30.39 | 444.18 | 1,652 | -334.22 | Upgrade
|
| Operating Cash Flow | 2,626 | 1,720 | 2,856 | 1,680 | 1,560 | 1,270 | Upgrade
|
| Operating Cash Flow Growth | 5.03% | -39.76% | 70.01% | 7.66% | 22.84% | -23.90% | Upgrade
|
| Capital Expenditures | -293.45 | -357.19 | -307.44 | -521.44 | -377.98 | -403.82 | Upgrade
|
| Sale of Property, Plant & Equipment | 11.33 | 10.96 | 5 | 3.72 | 26.02 | 2.03 | Upgrade
|
| Investment in Securities | 0.65 | 2.01 | - | 1.14 | -207.81 | -4.59 | Upgrade
|
| Other Investing Activities | -1,516 | -1,019 | - | 8.31 | 2.68 | 73.1 | Upgrade
|
| Investing Cash Flow | -1,797 | -1,363 | -302.44 | -508.28 | -557.09 | -333.28 | Upgrade
|
| Long-Term Debt Issued | - | 45 | 2,346 | 3,685 | 3,304 | 2,785 | Upgrade
|
| Total Debt Issued | 40 | 45 | 2,346 | 3,685 | 3,304 | 2,785 | Upgrade
|
| Short-Term Debt Repaid | - | - | - | - | - | -0.96 | Upgrade
|
| Long-Term Debt Repaid | - | -774.23 | -3,203 | -3,402 | -4,077 | -3,504 | Upgrade
|
| Total Debt Repaid | -65.1 | -774.23 | -3,203 | -3,402 | -4,077 | -3,505 | Upgrade
|
| Net Debt Issued (Repaid) | -25.1 | -729.23 | -856.83 | 282.87 | -773.63 | -719.91 | Upgrade
|
| Issuance of Common Stock | - | - | 1,188 | - | - | 1,611 | Upgrade
|
| Common Dividends Paid | -295.85 | -189.35 | -184.7 | -212.46 | -210.32 | -324.5 | Upgrade
|
| Other Financing Activities | -99.57 | -174.8 | -581.78 | -732.81 | -981.42 | -707.04 | Upgrade
|
| Financing Cash Flow | -420.52 | -1,093 | -435.32 | -662.41 | -1,965 | -140.87 | Upgrade
|
| Foreign Exchange Rate Adjustments | 49.21 | 32.07 | 94.24 | -40.08 | -44.35 | 9.68 | Upgrade
|
| Net Cash Flow | 457.23 | -703.83 | 2,212 | 468.9 | -1,007 | 805.67 | Upgrade
|
| Free Cash Flow | 2,332 | 1,363 | 2,548 | 1,158 | 1,182 | 866.32 | Upgrade
|
| Free Cash Flow Growth | 6.69% | -46.50% | 120.01% | -2.03% | 36.46% | -31.77% | Upgrade
|
| Free Cash Flow Margin | 20.13% | 11.29% | 19.66% | 8.31% | 9.42% | 7.10% | Upgrade
|
| Free Cash Flow Per Share | 1.74 | 1.07 | 2.20 | 0.98 | 1.00 | 0.75 | Upgrade
|
| Cash Income Tax Paid | 746.14 | 751.63 | 617.65 | 696.29 | 701.8 | 885.26 | Upgrade
|
| Levered Free Cash Flow | 1,763 | 1,796 | 1,634 | 621.88 | -96.55 | -331.79 | Upgrade
|
| Unlevered Free Cash Flow | 1,775 | 1,832 | 1,701 | 690.92 | -19.36 | -213.39 | Upgrade
|
| Change in Net Working Capital | -352.76 | -759.77 | -633.75 | 292.15 | 1,062 | 1,252 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.